Curcumin and EGCG Supplementation to Improve Serum BDNF and Mood Disturbance

Conditions

• Mood Disturbance

Eligibility Criteria

Sex

ALL

Age

18 Years - 50 Years

Healthy Volunteers

Accepted

Interventions

• Curcumin — DIETARY_SUPPLEMENT
  1,330 mg curcumin
• Epigallocatechin Gallate — DIETARY_SUPPLEMENT
  350 mg Epigallocatechin gallate (EGCG)
• Placebo — OTHER
  Placebo to be consumed after randomization.

Study Details

The goal of this randomized placebo controlled trial is to examine mood disturbance and serum brain derived neurotrophic factor (BDNF) in people (age 18-50) with DASS-21 subscale scores \>9. The main questions it aims to answer are: Does curcumin and EGCG supplementation improve mood disturbance symptomology? Does curcumin and EGCG supplementation increase serum BDNF? Researchers will compare intervention versus placebo. Participants will consume an 8-week supplement of both: * 1,330mg/day curcumin * 350mg/day epigallocatechin gallate (EGCG)

Key Dates

Start date

Sep 30, 2024

Status verified

Oct 2024

Primary completion

May 1, 2025

Completion

Aug 1, 2025

Study Design

Enrollment

64 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Curcumin and EGCG Supplementation
  Participants in the intervention group with consume 1,330mg/day curcumin with 350mg/day EGCG.
• Placebo Comparator: Placebo
  Participants will receive a placebo to consume everyday.

Primary Outcome Measure

Changes in total distress as measured via DASS-21 total score. [ Time Frame: 8-weeks ]

Central Contacts

• Aidan Cavanah, MSc
  2057893258
  [email protected]
• Andrew Fruge, PhD
  [email protected]

Locations (1)

Find similar trials in Auburn, AL